welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Welcome to your weekly digest of approaching regulatory and clinical readouts. Novavax is up 4% today thanks to topline results from a phase II trial showing that its Nanoflu influenza vaccine caused “vigorous immune responses” to four strains of flu, and that these responses were enhanced when the group’s Matrix-M adjuvant was added to the vaccine.
But an even more meaningful event is approaching. Novavax’s lead asset, a vaccine against respiratory syncytial virus, is in phase III, and after its disastrous failure two years ago in a study that was intended to be pivotal this is its last chance.
Resvax, also known as RSV F Vaccine since it targets the fusion protein of the virus, crashed out of the Resolve trial, testing it in prevention of moderate to severe RSV-associated lower respiratory tract disease, in mid-2016.
expertly curated content related to this topic
-
Update on Desmoid TumorsDesmoid tumors (DTs) are histologically ...
-
Familial and Hereditary Colon Cancerhttp://s3.gi.org/wp-content/uploads/2013...
-
High Rate of Recurrent Adenomatosis During Endoscopic Surveillance after Duodenectomy in Patients with Familial Aden...Advanced duodenal adenomatosis in patien...
-
The Role of High-resolution Endoscopy and Narrow-Band Imaging in the Evaluation of Upper GI Neoplasia in Familial Ad...BACKGROUND: The Spigelman classificatio...
-
Gardner Syndrome: Skin Manifestations, Differential Diagnosis and ManagementGardner syndrome is a variant of familia...
-
How a Colon Polyp Progress to Cancerhttp://adkblog.s3.amazonaws.com/content/...
-
A Novel APC Mosaicism in a Patient with Familial Adenomatous Polyposishttps://media.springernature.com/lw685/s...